- CEO
- Hetal Gala
- Full Time Employees
- 4,218
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 204, Udyog Kshetra Mumbai MH India 400080
- IPO Date
- Jan 30, 2023
- Business
- Aarti Pharmalabs Limited is a key developer and manufacturer of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, novel chemical entities, and xanthine derivatives. The company also extends comprehensive contract development and manufacturing organization (CDMO) services for drug substances and new chemical entities to global innovator and biotech firms. With a robust presence across India, its facilities produce a diverse range of generic APIs catering to cardiovascular, anti-diabetic, anti-cancer, and central nervous system therapeutic areas, alongside high-potency APIs. Aarti Pharmalabs holds a significant position as a leading Indian producer of xanthine derivatives, including caffeine, serving the pharmaceutical, nutraceutical, and beverage sectors worldwide, with exports reaching regulated markets such as the US, European Union, and Japan. Formed in November 2019, the company previously operated as Aarti Organics Limited and was later demerged from Aarti Industries Limited in October 2022 to become an independently listed entity.